Ronald H. Goldstein, MD
Professor, Medicine
Biography
Our laboratory is exploring the regulation of the alveolar matrix during the development of early emphysema and fibrosis. The loss of matrix substances results in emphysema whereas the excessive deposition of matrix substances results in pulmonary fibrosis. Employing the techniques of cellular and molecular biology, we are developing methods to modulating the levels of collagen, elastin and other key matrix substances in the alveolar wall. These approaches are studied in wild type and transgenic murine models of emphysema and fibrosis.
We have extensive experience in the diagnosis and management of individuals with pulmonary fibrosis. In human studies, our clinical experimental interest involves the use of novel substances to treat idiopathic pulmonary fibrosis (IPF). We participate in several clinical studies to evaluate the efficacy of these agents in the pathogenesis of IPF.
Research special interests include: Pulmonary Matrix Biology related to Pulmonary Fibrosis and Emphysema
Clinical special interests include: Pulmonary Fibrosis
Other Positions
- Research Assistant Professor, Biochemistry & Cell Biology, Boston University Chobanian & Avedisian School of Medicine
- Member, Pulmonary Center, Boston University
- Graduate Faculty (Primary Mentor of Grad Students), Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
- VA Boston Healthcare System
Education
- SUNY Downstate Medical Center, MD
- University of Wisconsin-Madison, BS
Publications
- Published on 5/20/2024
Johnson SW, Wang RS, Winter MR, Gillmeyer KR, Zeder K, Klings ES, Goldstein RH, Wiener RS, Maron BA. Cluster analysis identifies novel real-world lung disease-pulmonary hypertension subphenotypes: implications for treatment response. ERJ Open Res. 2024 May; 10(3). PMID: 38770008.
Read at: PubMed - Published on 7/1/2022
Johnson SW, Finlay L, Mathai SC, Goldstein RH, Maron BA. Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing. Pulm Circ. 2022 Jul; 12(3):e12126. PMID: 36092795.
Read at: PubMed - Published on 3/14/2022
Maron BA, Choudhary G, Goldstein RL, Garshick E, Jankowich M, Tucker TJS, LaCerda KA, Hattler B, Dempsey EC, Sadikot RT, Shapiro S, Rounds SI, Goldstein RH. Tadalafil for veterans with chronic obstructive pulmonary disease-pulmonary hypertension: A multicenter, placebo-controlled randomized trial. Pulm Circ. 2022 Jan; 12(1):e12043. PMID: 35506072.
Read at: PubMed - Published on 11/1/2020
Clark K, Goldstein R, Maron B, Breu AC. A Veteran Presenting With Chronic Progressive Dyspnea on Exertion. Fed Pract. 2020 Nov; 37(11):522-526. PMID: 33328718.
Read at: PubMed - Published on 7/27/2020
Maron BA, Brittan EL, Hess E, Waldo SW, Barón AE, Huang S, Goldstein RH, Assad T, Wertheim BM, Alba GA, Leopold JA, Olschewski H, Galiè N, Simonneau G, Kovacs G, Tedford RJ, Humbert M, Choudhary G. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med. 2020 09; 8(9):873-884. PMID: 32730752.
Read at: PubMed - Published on 2/12/2016
Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, Joynt KE, Kass DJ, Stephens T, Stanislawski MA, Swenson ER, Goldstein RH, Leopold JA, Zamanian RT, Elwing JM, Plomondon ME, Grunwald GK, Barón AE, Rumsfeld JS, Choudhary G. Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation. 2016 Mar 29; 133(13):1240-8. PMID: 26873944.
Read at: PubMed - Published on 12/1/2015
Berry NC, Manyoo A, Oldham WM, Stephens TE, Goldstein RH, Waxman AB, Tracy JA, Leary PJ, Leopold JA, Kinlay S, Opotowsky AR, Systrom DM, Maron BA. Protocol for exercise hemodynamic assessment: performing an invasive cardiopulmonary exercise test in clinical practice. Pulm Circ. 2015 Dec; 5(4):610-8. PMID: 26697168.
Read at: PubMed - Published on 12/1/2013
Maron BA, Goldstein RH, Rounds SI, Shapiro S, Jankowich M, Garshick E, Moy ML, Gagnon D, Choudhary G. Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial. Pulm Circ. 2013 Dec; 3(4):889-97. PMID: 25006405.
Read at: PubMed - Published on 5/10/2012
Golan-Gerstl R, Wallach-Dayan SB, Zisman P, Cardoso WV, Goldstein RH, Breuer R. Cellular FLICE-like inhibitory protein deviates myofibroblast fas-induced apoptosis toward proliferation during lung fibrosis. Am J Respir Cell Mol Biol. 2012 Sep; 47(3):271-9. PMID: 22582174.
Read at: PubMed - Published on 5/1/2012
Yu J, Taylor L, Rich C, Toselli P, Stone P, Green D, Warburton R, Hill N, Goldstein R, Polgar P. Transgenic expression of an altered angiotensin type I AT1 receptor resulting in marked modulation of vascular type I collagen. J Cell Physiol. 2012 May; 227(5):2013-21. PMID: 21751211.
Read at: PubMed
View 84 more publications: View full profile at BUMC